Purine synthesis and salvage pathway enzymes

Purine synthesis and salvage pathway enzymes are a group of biocatalysts responsible for the production and recycling of purine nucleotides, such as adenine and guanine, which are essential for DNA and RNA synthesis, energy transfer via ATP, and cellular signaling [1, 8, 11]. The de novo pathway constructs the purine ring from simple precursors like amino acids and carbon dioxide, while the salvage pathway recycles existing nucleobases and nucleosides to conserve cellular energy [1, 15, 18]. These enzymes are critical therapeutic targets in oncology, where antimetabolites like methotrexate and 6-mercaptopurine disrupt the rapid proliferation of cancer cells by depleting nucleotide pools [4, 12, 13]. Additionally, they are targeted in the treatment of gout through xanthine oxidase inhibitors like allopurinol and in autoimmune diseases using immunosuppressants like mycophenolate mofetil [5, 7, 14]. Dysregulation or genetic deficiency in these pathways can lead to severe metabolic and neurological disorders, such as Lesch-Nyhan syndrome [16, 17]. Understanding the coordination of these enzymes, often organized into a multi-enzyme complex called the purinosome, remains a key area of research for developing more selective metabolic inhibitors [12, 16].

Other names

Purine metabolism enzymesPurine biosynthetic pathway enzymesPurine salvage enzymesPurinosome components

Inhibition of specific enzymes within the de novo or salvage pathways to deplete intracellular nucleotide pools, thereby inhibiting DNA/RNA synthesis and cell division, or preventing the accumulation of metabolic byproducts like uric acid [3, 7, 12].